Skip to search formSkip to main contentSkip to account menu

AT 406

Known as: AT406 cpd, IAP Inhibitor AT-406, Pyrrolo(1,2-a)(1,5)diazocine-8-carboxamide, n-((1,1'-biphenyl)-2-ylmethyl)decahydro-5-(((2s)-2-(methylamino)-1-oxopropyl)amino)-3-(3-methyl-1-oxobutyl)-6-oxo-, (5s,8s,10ar) 
An orally bioavailable inhibitor of IAP (Inhibitor of Apoptosis Protein) family of proteins with potential apoptotic inducing and antineoplastic… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent TerminologySM 406

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
IAPs protect host target tissues from graft-versus-host disease in mice.
Inhibitors of apoptosis proteins (IAPs) regulate apoptosis, but little is known about the role of IAPs in the regulation of… 
2016
2016
IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis
High expression levels of Inhibitors of Apoptosis Proteins (IAPs) have been correlated with poor cancer prognosis and block the… 
2016
2016
Acquired cisplatin resistance in malignant pleural mesothelioma cells is reversed by both BH3-mimetic obatoclax and IAP-inhibitor AT-406
Background Cisplatin is used for treatment of malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC) but… 
2015
2015
Inhibition of Bcl-2 or IAP proteins does not provoke mutations in surviving cells.
2015
2015
Discovery of Novel, Potent, and Specific Cell‐Death Inducers in the Jurkat Acute Lymphoblastic Leukemia Cell Line
The limited clinical efficacy of many cancer therapeutics has initiated intense research efforts toward the discovery of novel… 
2014
2014
Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML).
7029 Background: Treatment of AML remains difficult due to the development of treatment resistance. Inhibitors of apoptosis… 
2014
2014
First-in-human, pharmacokinetic (PK), and pharmacodynamics (PD) phase I study of Debio1143 (AT-406) in patients with advanced cancer: Final results.
2532 Background: Inhibitors of apoptosis proteins (IAPs) modulate multiple processes, including caspases activation and NF-κB… 
2013
2013
Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM‐406/AT‐406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast…
The inhibitors of apoptosis proteins (IAPs) are a class of key apoptosis regulators overexpressed or dysregulated in cancer. SM… 
2012
2012
76 Preliminary Report of a First-in-human, Open-label, Multicenter, Phase I Study of AT-406 (Debio 1143), an Oral Small Molecule Multi-IAP Inhibitor, in Solid Tumors and Lymphomas
2009
2009
Abstract #1917: Synergistic effect of AT-406, a small molecule inhibitor of XIAP, with chemotherapy and tyrosine kinase inhibitors
X-linked inhibitor of apoptosis protein (XIAP) suppresses apoptosis in cells by inhibiting the apoptosis caspase-9 and caspase-3… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)